ToringinCAS# 1329-10-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1329-10-8 | SDF | Download SDF |
| PubChem ID | 101686456 | Appearance | Powder |
| Formula | C21H20O9 | M.Wt | 416.38 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 7-hydroxy-2-phenyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one | ||
| SMILES | C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)OC4C(C(C(C(O4)CO)O)O)O | ||
| Standard InChIKey | IRHAYEHCEVRWSB-QNDFHXLGSA-N | ||
| Standard InChI | InChI=1S/C21H20O9/c22-9-16-18(25)19(26)20(27)21(30-16)29-15-7-11(23)6-14-17(15)12(24)8-13(28-14)10-4-2-1-3-5-10/h1-8,16,18-23,25-27H,9H2/t16-,18-,19+,20-,21-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Toringin prevents the cis-effect of expanded CTG repeats in a stable PC12 cell transformant. |
| Targets | Caspase |
Toringin Dilution Calculator
Toringin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4017 mL | 12.0083 mL | 24.0165 mL | 48.033 mL | 60.0413 mL |
| 5 mM | 0.4803 mL | 2.4017 mL | 4.8033 mL | 9.6066 mL | 12.0083 mL |
| 10 mM | 0.2402 mL | 1.2008 mL | 2.4017 mL | 4.8033 mL | 6.0041 mL |
| 50 mM | 0.048 mL | 0.2402 mL | 0.4803 mL | 0.9607 mL | 1.2008 mL |
| 100 mM | 0.024 mL | 0.1201 mL | 0.2402 mL | 0.4803 mL | 0.6004 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Saikosaponin I
Catalog No.:BCN8605
CAS No.:103629-71-6
- Uvarigranol C
Catalog No.:BCN8604
CAS No.:172104-04-0
- 9-Methymyrrhone
Catalog No.:BCN8603
CAS No.:1809980-22-0
- Asperosaponin IV
Catalog No.:BCN8602
CAS No.:126778-93-6
- Rubipodanone A
Catalog No.:BCN8601
CAS No.:2170211-22-8
- Astraganoside
Catalog No.:BCN8600
CAS No.:1011711-05-9
- Isoastragaloside IV
Catalog No.:BCN8599
CAS No.:136033-55-1
- Eriosematin
Catalog No.:BCN8598
CAS No.:168010-17-1
- Licoflavone A
Catalog No.:BCN8597
CAS No.:61153-77-3
- Dehydronuciferine
Catalog No.:BCN8596
CAS No.:7630-74-2
- Ophiopogonoside A
Catalog No.:BCN8595
CAS No.:791849-22-4
- Jasminoside B
Catalog No.:BCN8594
CAS No.:214125-04-9
- Lucidenic acid B
Catalog No.:BCN8607
CAS No.:95311-95-8
- Cnidicin
Catalog No.:BCN8608
CAS No.:14348-21-1
- Gambogellic acid
Catalog No.:BCN8609
CAS No.:173867-04-4
- Protodeltonin
Catalog No.:BCN8611
CAS No.:94992-08-2
- Licoarylcoumarin
Catalog No.:BCN8612
CAS No.:125709-31-1
- Pratensein 7-O-glucopyranoside
Catalog No.:BCN8613
CAS No.:36191-03-4
- Plantainoside D
Catalog No.:BCN8614
CAS No.:147331-98-4
- Suspenoidside B
Catalog No.:BCN8615
CAS No.:2161432-08-0
- 7beta-Hydroxybufalin
Catalog No.:BCN8616
CAS No.:20143-97-9
- 6'-O-Cinnamoylharpagide
Catalog No.:BCN8617
CAS No.:1245572-24-0
- 3,4,4a,9,10,10a-heexahydro-8-hydroxy-1-(hydroxymethyl)-1,4a-dimethyl-7-(1-methylethyl)-phenanthrene-2(1H)-one
Catalog No.:BCN8618
CAS No.:262599-12-2
- Sargentol
Catalog No.:BCN8619
CAS No.:623928-18-7
Some flavonoids and DHEA-S prevent the cis-effect of expanded CTG repeats in a stable PC12 cell transformant.[Pubmed:15652241]
Biochem Pharmacol. 2005 Feb 1;69(3):503-16.
Expanded CUG triplet repeats carrying mRNA seem to be responsible for myotonic dystrophy type 1 (DM1). To study the pathogenesis of DM1, we constructed a DM1 cell culture model using a PC12 neuronal cell line and screened flavonoids that ameliorate this mRNA gain of function. The expanded 250 CTG repeat was subcloned into the 3'-untranslated region of the luciferase gene yielding a stable transformant of PC12 (CTG-250). The cytotoxicity of CTG-250 was evaluated by intracellular LDH activity, and the cis-effect by luciferase activity. To find agents that alter CTG-250 toxic effects, 235 bioflavonoids were screened. An increased cis-effect and cytotoxicity were found when CTG-250 was treated with nerve growth factor to induce differentiation. Western blotting with anti-caspase-3 antibody suggested that cell death was caused by apoptosis. Screening analysis confirmed that a flavone (Toringin), an isoflavones (genistein and formononetin), a flavanone (isosakuranetin), and DHEA-S prevent both the cytotoxicity and cis-effect of CTG-250 and that a flavanone (naringenin), isoflavone (ononin), and xanthylatin strongly inhibit the cis-effect of CTG repeats. In conclusion, we found that this neuronal cell line, which expresses the CUG repeat-bearing mRNA, showed cis-effects through the reporter gene and neuronal death after cell differentiation in vitro. However, some flavonoids and DHEA-S inhibit both the cis-effect and cytotoxicity, indicating that their chemical structures work to ameliorate both these toxic effects. This system makes it easy to evaluate the toxic effects of expanded CTG repeats and therefore should be useful for screening other DM1 treatments for their efficacies.
